The Dispersome® technology allows formulation of poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.
Our Dispersome® platform is based around a class of novel excipients to formulate poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.
By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability, therapeutic outcomes and convenience for patients.
Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities.
Zerion is a pharmaceutical development company improving the formulation of poorly soluble drugs (oral solid dosage forms) that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, Dispersome®, we aim to develop new treatment options for patients across all therapeutic areas.
Learn moreUp to 90 % of all new drug molecules are poorly soluble, which can be a problem as the drug must dissolve in order to be absorbed and reach its pharmacological target.
February 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) announces today that it has executed a long-term agreement with Arla Foods Ingredients covering the supply of its Lacprodan® BLG-100 for use as
February 22, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION), a Danish drug development company, is pleased to announce today to have entered into a strategic partnership with HOVIONE, a leading global specia
January 10, 2022 (COPENHAGEN, Denmark). The Danish drug development company, Zerion Pharma A/S (ZERION) has completed a new animal study (in dogs) that clearly demonstrates the potential of its patented Dispersome®